CHERYL WILLMAN, MD
Medical Practice in Albuquerque, NM
License number
New Mexico 85-126
Category
Medical Practice
Type
Clinical Pathology/Laboratory Medicine
Address
Address
2325 NE Unm Cancer Research - Treatment Ctr, Albuquerque, NM 87131
Phone
(505) 272-5622
Personal information
See more information about CHERYL WILLMAN at radaris.comName
Address
Phone
4633 Los Poblanos Cir NW, Los Ranchos, NM 87107
4633 Los Poblanos Cir NW, Albuquerque, NM 87107
Organization information
See more information about CHERYL WILLMAN at bizstanding.comUnm Cancer Center - Cheryl Willman MD
1201 Camino De Salud NE, Albuquerque, NM 87102
Categories:
Hematology Physicians & Surgeons, Oncology Physicians & Surgeons, Physicians & Surgeons
Site:
Phone:
(505) 272-4946 (Phone), (800) 432-6806 (Free)
Specialties:
Cancer Oncology, Breast Cancer, Dermatologic Cancers, Surgical Oncology, Radiation Oncology
Products:
(Bone & Soft Tissue), Cancer Care, Cancer Center, ...
Open Hours:
Hours by Appointment
Additional:
One of 61 Cancer Centers, Designated by the National, Cancer Institute, The Official Cancer Center Of, The State of New Mexico, Home To More Than 110, Researchers and 60, Cancer Doctors From Such, Ren...
Professional information
Gene Expression Classifiers For Relapse Free Survival And Minimal Residual Disease Improve Risk Classification And Outcome Prediction In Pediatric B-Precursor Acute Lymphoblastic Leukemia
US Patent:
2011023, Sep 22, 2011
Filed:
Nov 16, 2009
Appl. No.:
12/998474
Inventors:
Cheryl L. Willman - Albuquerque NM, US
Richard Harvey - Placitas NM, US
Huining Kang - Albuquerque NM, US
Edward Bedrick - Albuquerque NM, US
Xuefei Wang - Creve Coeur MO, US
Susan R. Atlas - Albuquerque NM, US
I-Ming Chen - Albuquerque NM, US
Richard Harvey - Placitas NM, US
Huining Kang - Albuquerque NM, US
Edward Bedrick - Albuquerque NM, US
Xuefei Wang - Creve Coeur MO, US
Susan R. Atlas - Albuquerque NM, US
I-Ming Chen - Albuquerque NM, US
International Classification:
C40B 40/06, C12Q 1/68, G01N 33/566, C12Q 1/44, C12Q 1/527, C12Q 1/48, G01N 33/573
US Classification:
506 16, 435 618, 435 617, 435 616, 435 61, 435 792, 435 19, 435 4, 435 15, 435 613, 435 71, 436501
Abstract:
The present invention relates to the identification of genetic markers patients with leukemia, especially including acute lymphoblastic leukemia (ALL) at high risk for relapse, especially high risk B-precursor acute lymphoblastic leukemia (B-ALL) and associated methods and their relationship to therapeutic outcome. The present invention also relates to diagnostic, prognostic and related methods using these genetic markers, as well as kits which provide microchips and/or immunoreagents for performing analysis on leukemia patients.
Identification Of Novel Subgroups Of High-Risk Pediatric Precursor B Acute Lymphoblastic Leukemia, Outcome Correlations And Diagnostic And Therapeutic Methods Related To Same
US Patent:
8568974, Oct 29, 2013
Filed:
Nov 14, 2008
Appl. No.:
12/734542
Inventors:
Cheryl L. Willman - Albuquerque NM, US
Richard Harvey - Placitas NM, US
George S. Davidson - Albuquerque NM, US
Xuefei Wang - Albuquerque NM, US
Susan R Atlas - Albuquerque NM, US
Edward J. Bedrick - Albuquerque NM, US
Iming L. Chen - Albuquerque NM, US
Richard Harvey - Placitas NM, US
George S. Davidson - Albuquerque NM, US
Xuefei Wang - Albuquerque NM, US
Susan R Atlas - Albuquerque NM, US
Edward J. Bedrick - Albuquerque NM, US
Iming L. Chen - Albuquerque NM, US
Assignee:
STC.UNM - Albuquerque NM
Sandia Corporation - Albuquerque NM
Sandia Corporation - Albuquerque NM
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435 61, 435 71
Abstract:
The present invention relates to the identification of genetic markers patients with high risk B-precursor acute lymphoblastic leukemia (B-ALL) and associated methods and their relationship to therapeutic outcome. The present invention also relates to diagnostic, prognostic and related methods using these genetic markers, as well as kits which provide microchips and/or immunoreagents for performing analysis on leukemia patients.
Director At Unm Cancer Center
Position:
Director at UNM Cancer Center
Location:
Albuquerque, New Mexico Area
Industry:
Medical Practice
Work:
UNM Cancer Center
-
Director
Dr. Cheryl Willman, Albuquerque NM - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
University New Mexico Cancer
1 University Of New Mexico SUITE 7-402, Albuquerque 87131
(505) 272-5622 (Phone)
University New Mexico Cancr Ctr
1201 Camino De Salud NE, Albuquerque 87102
(505) 272-4946 (Phone)
1 University Of New Mexico SUITE 7-402, Albuquerque 87131
(505) 272-5622 (Phone)
University New Mexico Cancr Ctr
1201 Camino De Salud NE, Albuquerque 87102
(505) 272-4946 (Phone)
Languages:
English
Hospitals:
University New Mexico Cancer
1 University Of New Mexico SUITE 7-402, Albuquerque 87131
University New Mexico Cancr Ctr
1201 Camino De Salud NE, Albuquerque 87102
Unm Hospital
2211 Lomas Blvd North #East, Albuquerque 87106
1 University Of New Mexico SUITE 7-402, Albuquerque 87131
University New Mexico Cancr Ctr
1201 Camino De Salud NE, Albuquerque 87102
Unm Hospital
2211 Lomas Blvd North #East, Albuquerque 87106
Education:
Medical School
Mayo Medical School
Graduated: 1981
U Nm Hosps
Mayo Medical School
Graduated: 1981
U Nm Hosps
Molecular Technologies For Improved Risk Classification And Therapy For Acute Lymphoblastic Leukemia In Children And Adults
US Patent:
2006014, Jun 29, 2006
Filed:
Nov 23, 2005
Appl. No.:
11/285976
Inventors:
Cheryl Willman - Albuquerque NM, US
Edward Bedrick - Albuquerque NM, US
Huining Kang - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
Edward Bedrick - Albuquerque NM, US
Huining Kang - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
The present invention relates to methods for predicting the outcome of therapeutic intervention in cases of leukemia, especially acute lymphoblastic leukemia in children and adults. The present invention evaluates a gene expression profile and identifies prognostic genes of cancers, in particular leukemia, more particularly B-precursor acute lymphoblastic leukemia (ALL). The present invention provides a method of determining prognosis of leukemia, in particular, acute lymphoblastic leukemia, more particularly B-precursor ALL and predicting therapeutic outcome of a patient. The method comprises the steps of first establishing the threshold value of at least three prognostic genes of leukemia, preferably at least eight prognostic genes, or preferably, as many as 26 prognostic genes. Then, the amount of the prognostic gene(s) from a leukemia patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene(s) which is indicative of therapeutic success or failure, whereby the prognostic outcome of the patient is determined/predicted.
Outcome Prediction And Risk Classification In Childhood Leukemia
US Patent:
2009020, Aug 13, 2009
Filed:
Jun 8, 2007
Appl. No.:
11/811436
Inventors:
Cheryl L. Willman - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
George S. Davidson - Albuquerque NM, US
Shawn B. Martin - Albuquerque NM, US
Susan R. Atlas - Albuquerque NM, US
Erik Andries - Rio Rancho NM, US
Huining Kang - Albuquerque NM, US
Jonathan J. Shuster - Gainesville FL, US
Xuefei Wang - Albuquerque NM, US
Richard C. Harvey - Placitas NM, US
David M. Haaland - Albuquerque NM, US
Jeffrey W. Potter - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
George S. Davidson - Albuquerque NM, US
Shawn B. Martin - Albuquerque NM, US
Susan R. Atlas - Albuquerque NM, US
Erik Andries - Rio Rancho NM, US
Huining Kang - Albuquerque NM, US
Jonathan J. Shuster - Gainesville FL, US
Xuefei Wang - Albuquerque NM, US
Richard C. Harvey - Placitas NM, US
David M. Haaland - Albuquerque NM, US
Jeffrey W. Potter - Albuquerque NM, US
International Classification:
A61K 38/17, C12N 15/12, C07H 21/04, C07K 14/47, A61K 31/711, A61P 35/02, C12N 5/10, C12N 15/85, C12Q 1/68, G01N 33/566
US Classification:
514 12, 536 235, 536 245, 530350, 4353201, 435 6, 435 71, 514 44, 435325
Abstract:
Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.
Outcome Prediction And Risk Classification In Childhood Leukemia
US Patent:
2006006, Mar 23, 2006
Filed:
Dec 5, 2003
Appl. No.:
10/729895
Inventors:
Cheryl Willman - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
George Davidson - Albuquerque NM, US
Shawn Martin - Albuquerque NM, US
Susan Atlas - Albuquerque NM, US
Erik Andries - Rio Rancho NM, US
Huining Kang - Albuquerque NM, US
Jonathan Shuster - Gainesville FL, US
Xuefei Wang - Albuquerque NM, US
Richard Harvey - Placitas NM, US
David Haaland - Albuquerque NM, US
Jeffrey Potter - Albuquerque NM, US
Paul Helman - Albuquerque NM, US
Robert Veroff - Albuquerque NM, US
George Davidson - Albuquerque NM, US
Shawn Martin - Albuquerque NM, US
Susan Atlas - Albuquerque NM, US
Erik Andries - Rio Rancho NM, US
Huining Kang - Albuquerque NM, US
Jonathan Shuster - Gainesville FL, US
Xuefei Wang - Albuquerque NM, US
Richard Harvey - Placitas NM, US
David Haaland - Albuquerque NM, US
Jeffrey Potter - Albuquerque NM, US
International Classification:
C12Q 1/68, C07H 21/04, C12P 21/06, C12N 15/09, C07K 14/705
US Classification:
435006000, 435069100, 435320100, 435325000, 530350000, 536023200
Abstract:
Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.
Interferon Regulatory Factors 1 And 2 In The Diagnosis Of Tumorigenicity
US Patent:
5652095, Jul 29, 1997
Filed:
Sep 24, 1993
Appl. No.:
8/126966
Inventors:
Tadatsugu Taniguchi - Ibaraki-shi, Osaka 567, JP
Cheryl L. Willman - Albuquerque NM
Maria G. Pallavicini - Livermore CA
Hisashi Harada - Osaka, JP
Nobuyuki Tanaka - Osaka, JP
Cheryl L. Willman - Albuquerque NM
Maria G. Pallavicini - Livermore CA
Hisashi Harada - Osaka, JP
Nobuyuki Tanaka - Osaka, JP
Assignee:
The Regents of the University of California - Oakland CA
The University of New Mexico - Albuquerque NM
The University of New Mexico - Albuquerque NM
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
The present invention relates, in general, to a method of diagnosing tumorigenic mammalian cells or the propensity of a mammalian cell to become tumorigenetic. Additionally, the present invention relates to a cloned cDNA or genomic DNA for reducing the propensity of a cell to become tumorigenic or suppressing tumorigenic phenotype of a cell; a method of reducing the propensity of a cell to become tumorigenic or suppressing the tumorigenic phenotype of a cell; a method of treating a patient suffering from or predisposed to subsequent cancer development; and a method of diagnosing tumorigenic tissue of a human or tissue predisposed to become tumorigenic.
Interferon Regulatory Factors 1 And 2 In The Diagnosis Of Tumorigenicity
US Patent:
5807836, Sep 15, 1998
Filed:
Feb 23, 1995
Appl. No.:
8/393565
Inventors:
Tadatsugu Taniguchi - Ibaraki-shi, Osaka 567, JP
Cheryl L. Willman - Albuquerque NM
Maria G. Pallavicini - Livermore CA
Hisashi Harada - Osaka, JP
Nobuyuki Tanaka - Osaka, JP
Cheryl L. Willman - Albuquerque NM
Maria G. Pallavicini - Livermore CA
Hisashi Harada - Osaka, JP
Nobuyuki Tanaka - Osaka, JP
Assignee:
The Regents of the University of California - Oakland CA
The University of New Mexico - Albuquerque NM
The University of New Mexico - Albuquerque NM
International Classification:
A01N 4304
US Classification:
514 44
Abstract:
The present invention relates, in general, to a method of diagnosing tumorigenic mammalian cells or the propensity of a mammalian cell to become tumorigenetic. Additionally, the present invention relates to a cloned cDNA or genomic DNA for reducing the propensity of a cell to become tumorigenic or suppressing tumorigenic phenotype of a cell; a method of reducing the propensity of a cell to become tumorigenic or suppressing the tumorigenic phenotype of a cell; a method of treating a patient suffering from or predisposed to subsequent cancer development; and a method of diagnosing tumorigenic tissue of a human or tissue predisposed to become tumorigenic.